Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Wells Fargo & Company's Rating of Rapport Therapeutics on 10/21/2026

On October 21, 2026, Wells Fargo & Company updated its outlook on Rapport Therapeutics (NASDAQ:RAPP) with the action "Lower Price Target", setting a price target of $50.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Wells Fargo & Company

DateCompanyAction
10/22/2026
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
Set Price Target
10/22/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
Lower Price Target
10/22/2026
Las Vegas Sands Corp. stock logo
LVS
Las Vegas Sands
Lower Price Target
10/22/2026
Reliance, Inc. stock logo
RS
Reliance
Boost Price Target
10/22/2026
Moody's Corporation stock logo
MCO
Moody's
Lower Price Target
10/22/2026
CME Group Inc. stock logo
CME
CME Group
Boost Price Target
More Ratings From Wells Fargo & Company